The purpose of this study is to assess the safety and preliminary effectiveness of the investigational drug RO5509554 alone and in combination with paclitaxel in patients with advanced solid tumors. RO5509554 blocks a protein called CSF1-R on white blood cells called M2 macrophages, which cause cancer cells to grow. It is hoped by blocking CSF1-R, RO5509554 may stop cancers from growing.
The patients in this study who will receive RO5509554 alone include those with pigmented villonodular synovitis, tenosynovial giant cell tumor, soft-tissue sarcoma, malignant mesothelioma, ovarian cancer, endometrial cancer, breast cancer, and pancreatic cancer. RO5509554 will be given with paclitaxel in patients with HER2-negative breast cancer.
RO5509554 is given intravenously (by vein).